Methods and compositions for treatment of retinoid-responsive conditions
US-2016194381-A1 · Jul 7, 2016 · US
Method for the treatment of acne by administering IL-1β antibody
US9707272B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9707272-B2 |
| Application number | US-201214232272-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 11, 2012 |
| Priority date | Jul 12, 2011 |
| Publication date | Jul 18, 2017 |
| Grant date | Jul 18, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides inhibitors capable of binding to a member of the inflammasome group comprised of IL-1β, IL-1 receptor type 1, NLRP3, ASC, Caspase-1 and cathepsin B with a dissociation constant of 10-8 mol/l or smaller for the prevention and treatment of acne, specifically an antibody, an antibody fragment, an antibody-like molecule, an oligopeptide of 6 to 30 amino acid residues, a nucleic acid aptamer molecule of 10 to 75 nucleotides in length or a soluble polypeptide comprising a contiguous amino acid sequence of at least 30 amino acids comprised within the protein sequence of a member of the group comprised of IL-1β, IL-1 receptor type 1, IL-1 receptor type 2, NLRP3, ASC and Caspase-1. Similarly, an interfering RNA or an antisense modulator of gene expression of IL-1β, I L-1β receptor type 1, NLRP3, ASC, Caspase-1 and cathepsin B are provided for the prevention or treatment of acne.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for the treatment of acne, comprising administering an effective amount of an inhibitor capable of binding to IL-1β, with a dissociation constant of at most 10 −8 mol/l, wherein the inhibitor is selected from an IL-1β antibody, and an antibody fragment. 2. The method according to claim 1 , wherein the inhibitor is selected from the group consisting of canakinumab and gevokizumab and LY21899102.
Assignees
Inventors
Classifications
Pyridazines; Hydrogenated pyridazines · CPC title
IL-1 · CPC title
comprising antibodies · CPC title
Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide · CPC title
- A61K38/2006Primary
IL-1 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9707272B2 cover?
- The invention provides inhibitors capable of binding to a member of the inflammasome group comprised of IL-1β, IL-1 receptor type 1, NLRP3, ASC, Caspase-1 and cathepsin B with a dissociation constant of 10-8 mol/l or smaller for the prevention and treatment of acne, specifically an antibody, an antibody fragment, an antibody-like molecule, an oligopeptide of 6 to 30 amino acid residues, a nucle…
- Who is the assignee on this patent?
- Jankovic Dragana, Kistowska Magdalena, Contassot Emmanuel, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification A61K38/2006. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).